论文部分内容阅读
采用间接酶联免疫法检测了１０１例临床诊断为乙型和非甲非乙型肝炎患者中抗－ＨＣＶ（Ｃ５５ＡＡ和ＮＳ_３６６ＡＡ的多肽抗体）结果提示：在ＨＢＶ相关性肝病及临床诊断的ＮＡＮＢ肝炎中，抗ＨＣＶ检出率为２１．２８％和５９．２６％。进一步分析发现ＨＢＶ感染及活动性复制，受血治疗和机体的基本状态差等是ＨＣＶ感染及肝脏损害的有利因素。
Indirect ELISA was used to detect the results of anti-HCV (polypeptide antibodies of C55AA and NS_366AA) in 101 clinically diagnosed patients with B and non-A non-B hepatitis, suggesting that in HBV-associated liver disease and clinically diagnosed NANB hepatitis , The detection rate of anti-HCV was 21.28% and 59.26%. Further analysis found that HBV infection and active replication, blood treatment and the poor basic status of the body is a favorable factor for HCV infection and liver damage.